Pricing Log in Create free account

Freenome, Inc (FRNM) vs GeneDx Holdings Corp. (WGS)

Freenome, Inc and GeneDx Holdings Corp. are both Diagnostics & Research companies. GeneDx Holdings Corp. is the larger, with a market value of $1.9B against $1.1B — 1.7× the size. Freenome, Inc has the higher net margin (0.00% vs −23.4%) and the higher return on invested capital (0.00% vs −27.7%). Across the 12 metrics below, Freenome, Inc leads on 9 and GeneDx Holdings Corp. on 3.

Valuation

Metric FRNM WGS Diagnostics & Research median
P/E n/m n/m 34.52
P/S n/m 4.24 4.24
P/B n/m 7.89 3.42
Price to free cash flow n/m n/m 33.51
EV/EBITDA n/m n/m 23.44
EV/Sales n/m 4.16 5.18
Earnings yield (2.98%) (5.61%) (1.50%)
Free cash flow yield (3.55%) (3.93%) 0.00%

Profitability

Metric FRNM WGS Diagnostics & Research median
Gross margin — 69.37% 48.32%
Operating margin 0.00% (20.34%) (5.68%)
Net margin 0.00% (23.40%) (4.10%)
Free cash flow margin 0.00% (16.68%) 0.00%
Return on equity 17.81% (40.80%) 0.00%
Return on assets (0.86%) (22.50%) (6.05%)
Return on invested capital 0.00% (27.70%) 0.00%

Growth

Metric FRNM WGS Diagnostics & Research median
Revenue growth (TTM) — 25.42% 8.99%
EPS growth (last fiscal year) (58.34%) 62.37% 20.36%
Revenue growth, 5-year CAGR — 18.98% 7.30%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric FRNM WGS Diagnostics & Research median
Debt to equity 0.00 0.40 0.01
Current ratio 0.20 3.30 2.27
Net debt to EBITDA 0.29 (10.13) 0.68

Dividend

Metric FRNM WGS Diagnostics & Research median
Dividend yield — — 0.67%
Payout ratio — — 0.20

Size

Metric FRNM WGS Diagnostics & Research median
Market cap 1.12b 1.92b 2.22b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack